PLGA particulate delivery systems for subunit vaccines: Linking particle properties to immunogenicity

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 4, 2016, Pages 1056-1069

  Silva, A L ^a   Soema, P C ^b   Slutter B ^a   Ossendorp, F ^c   Jiskoot, W ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b Intravacc (Institute for Translational Vaccinology)   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

adjuvant; antigen; delivery systems; dendritic cells; microparticles; nanoparticles; PLGA; subunit; vaccine

Indexed keywords

POLYGLACTIN; VACCINE; ANTIGEN; CANCER VACCINE; LACTIC ACID; NANOPARTICLE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SUBUNIT VACCINE;

ANTIGEN PRESENTING CELL; BIOCOMPATIBILITY; BIODEGRADABILITY; CROSS PRESENTATION; ENCAPSULATION; HYDROPHILICITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; PARTICLE SIZE; PHAGOCYTOSIS; REVIEW; ZETA POTENTIAL; CELLULAR IMMUNITY; CHEMISTRY; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; IMMUNOLOGY; VACCINE IMMUNOGENICITY;

ANTIGENS; CANCER VACCINES; CROSS-PRIMING; DENDRITIC CELLS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGENICITY, VACCINE; LACTIC ACID; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; VACCINES, SUBUNIT;

EID: 84961390365     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1117714     Document Type: Review

References (120)

1. J.Leleux, K.Roy. Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective. Adv Healthc Mater 2013; 2:72-94; PMID:23225517; http://dx.doi.org/10.1002/adhm.201200268
2. H.Bazin A brief history of the prevention of infectious diseases by immunisations. Comp Immunol Microbiol Infect Dis 2003; 26:293-308; PMID:12818618; http://dx.doi.org/10.1016/S0147-9571(03)00016-X
3. J.Parrino, B.S.Graham. Smallpox vaccines: Past, present, and future. J Allergy Clin Immunol 2006; 118:1320-6; PMID:17157663; http://dx.doi.org/10.1016/j.jaci.2006.09.037
4. D.T.O'Hagan, R.Rappuoli. Novel approaches to vaccine delivery. Pharm Res 2004; 21:1519-30; PMID:15497674; http://dx.doi.org/10.1023/B:PHAM.0000041443.17935.33
5. A.Salvador, M.Igartua, R.M.Hernandez, J.L.Pedraz. An overview on the field of micro- and nanotechnologies for synthetic Peptide-based vaccines. J Drug Deliv 2011; 2011:181646; PMID:21773041; http://dx.doi.org/10.1155/2011/181646
6. P.Vandana, P.Priyanka. Potential of Nanocarriers in Antigen Delivery: The Path to Successful Vaccine Delivery. Nanocarriers 2014; 1:10-45
7. S.L.Demento, A.L.Siefert, A.Bandyopadhyay, F.A.Sharp, T.M.Fahmy. Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. Trends Biotechnol 2011; 29:294-306; PMID:21459467; http://dx.doi.org/10.1016/j.tibtech.2011.02.004
8. M.Black, A.Trent, M.Tirrell, C.Olive. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert Rev Vaccines 2010; 9:157-73; PMID:20109027; http://dx.doi.org/10.1586/erv.09.160
9. S.L.Demento, W.Cui, J.M.Criscione, E.Stern, J.Tulipan, S.M.Kaech, T.M.Fahmy. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials 2012; 33:4957-64; PMID:22484047; http://dx.doi.org/10.1016/j.biomaterials.2012.03.041
10. P.Elamanchili, C.M.Lutsiak, S.Hamdy, M.Diwan, J.Samuel. “Pathogen-mimicking” nanoparticles for vaccine delivery to dendritic cells. J Immunother 2007; 30:378-95; PMID:17457213; http://dx.doi.org/10.1097/CJI.0b013e31802cf3e3
11. L.J.Cruz, R.A.Rosalia, J.W.Kleinovink, F.Rueda, C.W.Lowik, F.Ossendorp. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. J Control Release 2014; 192:209-18; PMID:25068703; http://dx.doi.org/10.1016/j.jconrel.2014.07.040
12. L.J.Cruz, P.J.Tacken, R.Fokkink, B.Joosten, M.C.Stuart, F.Albericio, R.Torensma, C.G.Figdor. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J Control Release 2010; 144:118-26; PMID:20156497; http://dx.doi.org/10.1016/j.jconrel.2010.02.013
13. J.G.van den Boorn, G.Hartmann. Turning tumors into vaccines: co-opting the innate immune system. Immunity 2013; 39:27-37; PMID:23890061; http://dx.doi.org/10.1016/j.immuni.2013.07.011
14. R.A.Rosalia, L.J.Cruz, S.van Duikeren, A.T.Tromp, A.L.Silva, W.Jiskoot, T.de Gruijl, C.Lowik, J.Oostendorp, S.H.van der Burg, et al. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses. Biomaterials 2015; 40:88-97; PMID:25465442; http://dx.doi.org/10.1016/j.biomaterials.2014.10.053
15. S.Zwaveling, S.C.Ferreira Mota, J.Nouta, M.Johnson, G.B.Lipford, R.Offringa, S.H.van der Burg, C.J.Melief. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169:350-8; PMID:12077264; http://dx.doi.org/10.4049/jimmunol.169.1.350
16. H.Shen, A.L.Ackerman, V.Cody, A.Giodini, E.R.Hinson, P.Cresswell, R.L.Edelson, W.M.Saltzman, D.J.Hanlon. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006; 117:78-88; PMID:16423043; http://dx.doi.org/10.1111/j.1365-2567.2005.02268.x
17. R.C.Mundargi, V.R.Babu, V.Rangaswamy, P.Patel, T.M.Aminabhavi. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 2008; 125:193-209; PMID:18083265; http://dx.doi.org/10.1016/j.jconrel.2007.09.013
18. D.T.O'Hagan, H.Jeffery, M.J.Roberts, J.P.McGee, S.S.Davis. Controlled release microparticles for vaccine development. Vaccine 1991; 9:768-71; PMID:1759495; http://dx.doi.org/10.1016/0264-410X(91)90295-H
19. R.A.Jain The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials 2000; 21:2475-90; PMID:11055295; http://dx.doi.org/10.1016/S0142-9612(00)00115-0
20. N.L.Ignjatovic, Z.R.Ajdukovic, V.P.Savic, D.P.Uskokovic. Size effect of calcium phosphate coated with poly-DL-lactide- co-glycolide on healing processes in bone reconstruction. J Biomed Mater Res Part B Appl Biomater 2010; 94:108-17; PMID:20524184
21. M.Shive, J.Anderson. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997; 28:5-24; PMID:10837562; http://dx.doi.org/10.1016/S0169-409X(97)00048-3
22. C.E.Astete, C.M.Sabliov. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 2006; 17:247-89; PMID:16689015; http://dx.doi.org/10.1163/156856206775997322
23. S.Mohammadi-Samani, B.Taghipour. PLGA micro and nanoparticles in delivery of peptides and proteins; problems and approaches. Pharm Dev Technol 2014; 20(4):385-93; PMID:24483777
24. J.M.Silva, M.Videira, R.Gaspar, V.Preat, H.F.Florindo. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release 2013; 168:179-99; PMID:23524187; http://dx.doi.org/10.1016/j.jconrel.2013.03.010
25. A.Sorkin, M.Von Zastrow. Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 2002; 3:600-14; PMID:12154371; http://dx.doi.org/10.1038/nrm883
26. B.S.Zolnik, D.J.Burgess. Effect of acidic pH on PLGA microsphere degradation and release. J Control Release 2007; 122:338-44; PMID:17644208; http://dx.doi.org/10.1016/j.jconrel.2007.05.034
27. J.Y.Yoo, J.M.Kim, K.S.Seo, Y.K.Jeong, H.B.Lee, G.Khang. Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method. Biomed Mater Eng 2005; 15:279-88; PMID:16010036
28. T.M.Fahmy, S.L.Demento, M.J.Caplan, I.Mellman, W.M.Saltzman. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine (Lond) 2008; 3:343-55; PMID:18510429; http://dx.doi.org/10.2217/17435889.3.3.343
29. S.Jain, D.T.O'Hagan, M.Singh. The long-term potential of biodegradable poly(lactide-co-glycolide) microparticles as the next-generation vaccine adjuvant. Expert Rev Vaccines 2011; 10:1731-42; PMID:22085176; http://dx.doi.org/10.1586/erv.11.126
30. N.Samadi, A.Abbadessa, A.Di Stefano, C.F.van Nostrum, T.Vermonden, S.Rahimian, E.A.Teunissen, M.J.van Steenbergen, M.Amidi, W.E.Hennink. The effect of lauryl capping group on protein release and degradation of poly(D,L-lactic-co-glycolic acid) particles. J Control Release 2013; 172:436-43; PMID:23751568; http://dx.doi.org/10.1016/j.jconrel.2013.05.034
31. I.Bala, S.Hariharan, M.N.Kumar. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004; 21:387-422; PMID:15719481; http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.v21.i5.20
32. N.Jawahar, S.Meyyanathan. Polymeric nanoparticles for drug delivery and targeting: A comprehensive review. Int J Health Allied Sci 2012; 1:217-23; http://dx.doi.org/10.4103/2278-344X.107832
33. P.Johansen, T.Storni, L.Rettig, Z.Qiu, A.Der-Sarkissian, K.A.Smith, V.Manolova, K.S.Lang, G.Senti, B.Mullhaupt, et al. Antigen kinetics determines immune reactivity. Proc Natl Acad Sci U S A 2008; 105:5189-94; PMID:18362362; http://dx.doi.org/10.1073/pnas.0706296105
34. V.B.Joshi, S.M.Geary, A.K.Salem. Biodegradable particles as vaccine delivery systems: size matters. AAPS J 2013; 15:85-94; PMID:23054976; http://dx.doi.org/10.1208/s12248-012-9418-6
35. M.O.Oyewumi, A.Kumar, Z.Cui. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010; 9:1095-107; PMID:20822351; http://dx.doi.org/10.1586/erv.10.89
36. A.L.Silva, R.A.Rosalia, A.Sazak, M.G.Carstens, F.Ossendorp, J.Oostendorp, W.Jiskoot. Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation. Eur J Pharm Biopharm 2013; 83:338-45; PMID:23201055; http://dx.doi.org/10.1016/j.ejpb.2012.11.006
37. G.Wang, H.Uludag. Recent developments in nanoparticle-based drug delivery and targeting systems with emphasis on protein-based nanoparticles. Expert Opin Drug Deliv 2008; 5:499-515; PMID:18491978; http://dx.doi.org/10.1517/17425247.5.5.499
38. A.Link, F.Zabel, Y.Schnetzler, A.Titz, F.Brombacher, M.F.Bachmann. Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol 2012; 188:3724-33; PMID:22427639; http://dx.doi.org/10.4049/jimmunol.1103312
39. V.Manolova, A.Flace, M.Bauer, K.Schwarz, P.Saudan, M.F.Bachmann. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008; 38:1404-13; PMID:18389478; http://dx.doi.org/10.1002/eji.200737984
40. L.C.Simon, C.M.Sabliov. The effect of nanoparticle properties, detection method, delivery route and animal model on poly(lactic-co-glycolic) acid nanoparticles biodistribution in mice and rats. Drug Metab Rev 2013; PMID:24303927
41. T.Fifis, A.Gamvrellis, B.Crimeen-Irwin, G.A.Pietersz, J.Li, P.L.Mottram, I.F.McKenzie, M.Plebanski. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 2004; 173:3148-54; PMID:15322175; http://dx.doi.org/10.4049/jimmunol.173.5.3148
42. I.Gutierro, R.M.Hernandez, M.Igartua, A.R.Gascon, J.L.Pedraz. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine 2002; 21:67-77; PMID:12443664; http://dx.doi.org/10.1016/S0264-410X(02)00435-8
43. K.K.Tran, H.Shen. The role of phagosomal pH on the size-dependent efficiency of cross-presentation by dendritic cells. Biomaterials 2009; 30:1356-62; PMID:19091401; http://dx.doi.org/10.1016/j.biomaterials.2008.11.034
44. S.D.Xiang, A.Scholzen, G.Minigo, C.David, V.Apostolopoulos, P.L.Mottram, M.Plebanski. Pathogen recognition and development of particulate vaccines: does size matter? Methods 2006; 40:1-9; PMID:16997708; http://dx.doi.org/10.1016/j.ymeth.2006.05.016
45. F.A.Sharp, D.Ruane, B.Claass, E.Creagh, J.Harris, P.Malyala, M.Singh, D.T.O'Hagan, V.Petrilli, J.Tschopp, et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc Natl Acad Sci U S A 2009; 106:870-5; PMID:19139407; http://dx.doi.org/10.1073/pnas.0804897106
46. M.D.Joshi, W.J.Unger, G.Storm, Y.van Kooyk, E.Mastrobattista. Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release 2012; 161:25-37; PMID:22580109; http://dx.doi.org/10.1016/j.jconrel.2012.05.010
47. A.L.Silva, R.A.Rosalia, E.Varypataki, S.Sibuea, F.Ossendorp, W.Jiskoot. Poly-(lactic-co-glycolic-acid)-based particulate vaccines: Particle uptake by dendritic cells is a key parameter for immune activation. Vaccine 2015; 33(7):847-54
48. Y.K.Katare, T.Muthukumaran, A.K.Panda. Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles. Int J Pharm 2005; 301:149-60; PMID:16023313; http://dx.doi.org/10.1016/j.ijpharm.2005.05.028
49. C.Thomas, V.Gupta, F.Ahsan. Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles. Pharm Res 2010; 27:905-19; PMID:20232117; http://dx.doi.org/10.1007/s11095-010-0094-x
50. V.Kanchan, A.K.Panda. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 2007; 28:5344-57; PMID:17825905; http://dx.doi.org/10.1016/j.biomaterials.2007.08.015
51. R.S.Raghuvanshi, Y.K.Katare, K.Lalwani, M.M.Ali, O.Singh, A.K.Panda. Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants. Int J Pharm 2002; 245:109-21; PMID:12270248; http://dx.doi.org/10.1016/S0378-5173(02)00342-3
52. Lee YR, Lee YH, Im SA, Kim K, Lee CK. Formulation and characterization of antigen-loaded PLGA nanoparticles for efficient cross-priming of the antigen. Immune Netw 2011; 11:163-8.
53. M.T.Aguado Future approaches to vaccine development: single-dose vaccines using controlled-release delivery systems. Vaccine 1993; 11:596-7; PMID:8488720; http://dx.doi.org/10.1016/0264-410X(93)90241-O
54. I.Preis, R.S.Langer. A single-step immunization by sustained antigen release. J Immunol Methods 1979; 28:193-7; PMID:469267; http://dx.doi.org/10.1016/0022-1759(79)90341-7
55. J.F.Correia-Pinto, N.Csaba, M.J.Alonso. Vaccine delivery carriers: insights and future perspectives. Int J Pharm 2013; 440:27-38; PMID:22561794; http://dx.doi.org/10.1016/j.ijpharm.2012.04.047
56. L.Dailey. New poly (lactic-co-glycolic acid) derivatives: Modular polymers with tailored properties. Drug Discov Today Technol 2005; 2(1):7-13; PMID:24981749
57. Y.Yeo, K.Park. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch Pharm Res 2004; 27:1-12; PMID:14969330; http://dx.doi.org/10.1007/BF02980037
58. H.Sah, R.Toddywala, Y.W.Chien. Continuous release of proteins from biodegradable microcapsules and in vivo evaluation of their potential as a vaccine adjuvant. J Controlled Release 1995; 35:137-44; http://dx.doi.org/10.1016/0168-3659(95)00029-8
59. H.Sah, R.Toddywala, Y.W.Chien. The influence of biodegradable microcapsule formulations on the controlled release of a protein. J Controlled Release 1994; 30:201-11; http://dx.doi.org/10.1016/0168-3659(94)90026-4
60. J.Panyam, M.M.Dali, S.K.Sahoo, W.Ma, S.S.Chakravarthi, G.L.Amidon, R.J.Levy, V.Labhasetwar. Polymer degradation and in vitro release of a model protein from poly(d,l-lactide-co-glycolide) nano- and microparticles. J Controlled Release 2003; 92:173-87; http://dx.doi.org/10.1016/S0168-3659(03)00328-6
61. N.Leelarasamee, S.A.Howard, C.J.Malanga, L.A.Luzzi, T.F.Hogan, S.J.Kandzari, J.K.Ma. Kinetics of drug release from polylactic acid-hydrocortisone microcapsules. J Microencapsul 1986; 3:171-9; PMID:3508185; http://dx.doi.org/10.3109/02652048609031571
62. Y.Zhang, S.Zale, L.Sawyer, H.Bernstein. Effects of metal salts on poly(DL-lactide-co-glycolide) polymer hydrolysis. J Biomed Mater Res 1997; 34:531-8; PMID:9054536; http://dx.doi.org/10.1002/(SICI)1097-4636(19970315)34:4<531::AID-JBM13>3.0.CO;2-F
63. H.M.Mansour, M.Sohn, A.Al-Ghananeem, P.P.Deluca. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Int J Mol Sci 2010; 11:3298-322; PMID:20957095; http://dx.doi.org/10.3390/ijms11093298
64. T.Govender, S.Stolnik, M.C.Garnett, L.Illum, S.S.Davis. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 1999; 57:171-85; PMID:9971898; http://dx.doi.org/10.1016/S0168-3659(98)00116-3
65. Y.Hailemichael, Z.Dai, N.Jaffarzad, Y.Ye, M.A.Medina, X.F.Huang, S.M.Dorta-Estremera, N.R.Greeley, G.Nitti, W.Peng, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 2013; 19:465-72; PMID:23455713; http://dx.doi.org/10.1038/nm.3105
66. V.Kanchan, Y.K.Katare, A.K.Panda. Memory antibody response from antigen loaded polymer particles and the effect of antigen release kinetics. Biomaterials 2009; 30:4763-76; PMID:19540583; http://dx.doi.org/10.1016/j.biomaterials.2009.05.075
67. Y.Waeckerle-Men, E.U.Allmen, B.Gander, E.Scandella, E.Schlosser, G.Schmidtke, H.P.Merkle, M.Groettrup. Encapsulation of proteins and peptides into biodegradable poly(D,L-lactide-co-glycolide) microspheres prolongs and enhances antigen presentation by human dendritic cells. Vaccine 2006; 24:1847-57; PMID:16288821; http://dx.doi.org/10.1016/j.vaccine.2005.10.032
68. W.Zhang, L.Wang, Y.Liu, X.Chen, Q.Liu, J.Jia, T.Yang, S.Qiu, G.Ma. Immune responses to vaccines involving a combined antigen–nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials 2014; 35:6086-97; PMID:24780166; http://dx.doi.org/10.1016/j.biomaterials.2014.04.022
69. C.Thomas, V.Gupta, F.Ahsan. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses. Int J Pharm 2009; 379:41-50; PMID:19524654; http://dx.doi.org/10.1016/j.ijpharm.2009.06.006
70. M.Skwarczynski, I.Toth. Recent advances in peptide-based subunit nanovaccines. Nanomedicine (Lond) 2014; 9:2657-69; PMID:25529569; http://dx.doi.org/10.2217/nnm.14.187
71. S.Fischer, E.Uetz-von Allmen, Y.Waeckerle-Men, M.Groettrup, H.P.Merkle, B.Gander. The preservation of phenotype and functionality of dendritic cells upon phagocytosis of polyelectrolyte-coated PLGA microparticles. Biomaterials 2007; 28:994-1004; PMID:17118442; http://dx.doi.org/10.1016/j.biomaterials.2006.10.034
72. C.Wischke, H.H.Borchert, J.Zimmermann, I.Siebenbrodt, D.R.Lorenzen. Stable cationic microparticles for enhanced model antigen delivery to dendritic cells. J Control Release 2006; 114:359-68; PMID:16889866; http://dx.doi.org/10.1016/j.jconrel.2006.06.020
73. K.S.Jaganathan, S.P.Vyas. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 2006; 24:4201-11; PMID:16446012; http://dx.doi.org/10.1016/j.vaccine.2006.01.011
74. B.Slutter, S.Bal, C.Keijzer, R.Mallants, N.Hagenaars, I.Que, E.Kaijzel, W.van Eden, P.Augustijns, C.Lowik, et al. Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine 2010; 28:6282-91; PMID:20638455; http://dx.doi.org/10.1016/j.vaccine.2010.06.121
75. J.M.Martinez Gomez, N.Csaba, S.Fischer, A.Sichelstiel, T.M.Kundig, B.Gander, P.Johansen. Surface coating of PLGA microparticles with protamine enhances their immunological performance through facilitated phagocytosis. J Control Release 2008; 130:161-7; PMID:18588928; http://dx.doi.org/10.1016/j.jconrel.2008.06.003
76. J.M.Martinez Gomez, S.Fischer, N.Csaba, T.M.Kundig, H.P.Merkle, B.Gander, P.Johansen. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res 2007; 24:1927-35; PMID:17541735; http://dx.doi.org/10.1007/s11095-007-9318-0
77. S.Fischer, E.Schlosser, M.Mueller, N.Csaba, H.P.Merkle, M.Groettrup, B.Gander. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J Drug Target 2009; 17:652-61; http://dx.doi.org/10.1080/10611860903119656
78. M.L.De Temmerman, J.Rejman, J.Demeester, D.J.Irvine, B.Gander, S.C.De Smedt. Particulate vaccines: on the quest for optimal delivery and immune response. Drug Discov Today 2011; 16:569-82; PMID:21570475; http://dx.doi.org/10.1016/j.drudis.2011.04.006
79. E.Schlosser, M.Mueller, S.Fischer, S.Basta, D.H.Busch, B.Gander, M.Groettrup. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine 2008; 26:1626-37; PMID:18295941; http://dx.doi.org/10.1016/j.vaccine.2008.01.030
80. M.Diwan, M.Tafaghodi, J.Samuel. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Controlled Release 2002; 85:247-62; http://dx.doi.org/10.1016/S0168-3659(02)00275-4
81. B.San Román, J.M.Irache, S.Gómez, N.Tsapis, C.Gamazo, M.S.Espuelas. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology. Eur J Pharm Biopharm 2008; 70:98-108; http://dx.doi.org/10.1016/j.ejpb.2008.03.015
82. A.Heit, F.Schmitz, T.Haas, D.H.Busch, H.Wagner. Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity. Eur J Immunol 2007; 37:2063-74; PMID:17628858; http://dx.doi.org/10.1002/eji.200737169
83. A.Heit, F.Schmitz, M.O'Keeffe, C.Staib, D.H.Busch, H.Wagner, K.M.Huster. Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J Immunol 2005; 174:4373-80; PMID:15778402; http://dx.doi.org/10.4049/jimmunol.174.7.4373
84. C.Wischke, J.Zimmermann, B.Wessinger, A.Schendler, H.H.Borchert, J.H.Peters, T.Nesselhut, D.R.Lorenzen. Poly(I:C) coated PLGA microparticles induce dendritic cell maturation. Int J Pharm 2009; 365:61-8; PMID:18812217; http://dx.doi.org/10.1016/j.ijpharm.2008.08.039
85. M.Mueller, E.Schlosser, B.Gander, M.Groettrup. Tumor eradication by immunotherapy with biodegradable PLGA microspheres–an alternative to incomplete Freund's adjuvant. Int J Cancer 2011; 129:407-16; PMID:21207410; http://dx.doi.org/10.1002/ijc.25914
86. Y.R.Lee, Y.H.Lee, S.A.Im, I.H.Yang, G.W.Ahn, K.Kim, C.K.Lee. Biodegradable nanoparticles containing TLR3 or TLR9 agonists together with antigen enhance MHC-restricted presentation of the antigen. Arch Pharm Res 2010; 33:1859-66; PMID:21116790; http://dx.doi.org/10.1007/s12272-010-1119-z
87. K.D.Newman, J.Samuel, G.Kwon. Ovalbumin peptide encapsulated in poly(d,l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J Control Release 1998; 54:49-59; PMID:9741903; http://dx.doi.org/10.1016/S0168-3659(97)00142-9
88. K.D.Newman, D.L.Sosnowski, G.S.Kwon, J.Samuel. Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J Pharm Sci 1998; 87:1421-7; PMID:9811500; http://dx.doi.org/10.1021/js980070s
89. S.Hamdy, P.Elamanchili, A.Alshamsan, O.Molavi, T.Satou, J.Samuel. Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles. J Biomed Materials Res Part A 2007; 81:652-62; http://dx.doi.org/10.1002/jbm.a.31019
90. S.Hamdy, O.Molavi, Z.Ma, A.Haddadi, A.Alshamsan, Z.Gobti, S.Elhasi, J.Samuel, A.Lavasanifar. Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity. Vaccine 2008; 26:5046-57; PMID:18680779; http://dx.doi.org/10.1016/j.vaccine.2008.07.035
91. C.S.W.Chong, M.Cao, W.W.Wong, K.P.Fischer, W.R.Addison, G.S.Kwon, D.L.Tyrrell, J.Samuel. Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Controlled Rel 2005; 102:85-99; http://dx.doi.org/10.1016/j.jconrel.2004.09.014
92. M.E.Lutsiak, G.S.Kwon, J.Samuel. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J Pharm Pharmacol 2006; 58:739-47; PMID:16734975; http://dx.doi.org/10.1211/jpp.58.6.0004
93. Z.Zhang, S.Tongchusak, Y.Mizukami, Y.J.Kang, T.Ioji, M.Touma, B.Reinhold, D.B.Keskin, E.L.Reinherz, T.Sasada. Induction of anti-tumor cytotoxic T cell responses through PLGA-nanoparticle mediated antigen delivery. Biomaterials 2011; 32:3666-78; PMID:21345488; http://dx.doi.org/10.1016/j.biomaterials.2011.01.067
94. J.Kazzaz, M.Singh, M.Ugozzoli, J.Chesko, E.Soenawan, D.T.O'Hagan. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release 2006; 110:566-73; PMID:16360956; http://dx.doi.org/10.1016/j.jconrel.2005.10.010
95. D.F.Nixon, C.Hioe, P.D.Chen, Z.Bian, P.Kuebler, M.L.Li, H.Qiu, X.M.Li, M.Singh, J.Richardson, et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996; 14:1523-30; PMID:9014294; http://dx.doi.org/10.1016/S0264-410X(96)00099-0
96. R.A.Rosalia Co-encapsulation of synthetic long peptide antigen and Toll like receptor 2 ligand in poly-(lactic-co-glycolic-acid) particles results in sustained MHC class I cross-presentation by dendritic cells. In: Department of Immunohematology FoMLUMCL, Leiden University, ed. Particulate based vaccines for cancer immunotherapy: Leiden University, 2014:95-121
97. S.Khan, M.S.Bijker, J.J.Weterings, H.J.Tanke, G.J.Adema, T.van Hall, J.W.Drijfhout, C.J.Melief, H.S.Overkleeft, G.A.van der Marel, et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem 2007; 282:21145-59; PMID:17462991; http://dx.doi.org/10.1074/jbc.M701705200
98. S.Khan, J.J.Weterings, C.M.Britten, A.R.de Jong, D.Graafland, C.J.Melief, S.H.van der Burg, G.van der Marel, H.S.Overkleeft, D.V.Filippov, et al. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells. Mol Immunol 2009; 46:1084-91; PMID:19027958; http://dx.doi.org/10.1016/j.molimm.2008.10.006
99. G.G.Zom, S.Khan, D.V.Filippov, F.Ossendorp. TLR ligand-peptide conjugate vaccines: toward clinical application. Adv Immunol 2012; 114:177-201; PMID:22449782; http://dx.doi.org/10.1016/B978-0-12-396548-6.00007-X
100. G.G.Zom, S.Khan, C.M.Britten, V.Sommandas, M.G.Camps, N.M.Loof, C.F.Budden, N.J.Meeuwenoord, D.V.Filippov, G.A.van der Marel, et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates. Cancer Immunol Res 2014; 2:756-64.; PMID:24950688;PMID:24950688; http://dx.doi.org/10.1158/2326-6066.CIR-13-0223
101. M.Singh, J.Kazzaz, M.Ugozzoli, P.Malyala, J.Chesko, D.T.O'Hagan. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Delivery 2006; 3:115-20; http://dx.doi.org/10.2174/156720106775197565
102. Singh M, Ott G, Kazzaz J, Ugozzoli M, Briones M, Donnelly J, O'Hagan DT. Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharm Res 2001; 18:1476-9.
103. H.Sah, L.A.Thoma, H.R.Desu, E.Sah, G.C.Wood. Concepts and practices used to develop functional PLGA-based nanoparticulate systems. Int J Nano Med 2013; 8:747-65; http://dx.doi.org/10.2147/IJN.S40579
104. S.Hamdy, A.Haddadi, R.W.Hung, A.Lavasanifar. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations. Adv Drug Deliv Rev 2011; 63:943-55; PMID:21679733; http://dx.doi.org/10.1016/j.addr.2011.05.021
105. T.E.Rajapaksa, M.Stover-Hamer, X.Fernandez, H.A.Eckelhoefer, D.D.Lo. Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery. J Controlled Release 2010; 142:196-205; http://dx.doi.org/10.1016/j.jconrel.2009.10.033
106. P.N.Gupta, K.Khatri, A.K.Goyal, N.Mishra, S.P.Vyas. M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 2007; 15:701-13; http://dx.doi.org/10.1080/10611860701637982
107. M.Garinot, V.Fievez, V.Pourcelle, F.Stoffelbach, A.des Rieux, L.Plapied, I.Theate, H.Freichels, C.Jerome, J.Marchand-Brynaert, et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 2007; 120:195-204; PMID:17586081; http://dx.doi.org/10.1016/j.jconrel.2007.04.021
108. N.Brandhonneur, F.Chevanne, V.Vie, B.Frisch, R.Primault, M.F.Le Potier, P.Le Corre. Specific and non-specific phagocytosis of ligand-grafted PLGA microspheres by macrophages. Eur J Pharm Sci 2009; 36:474-85; PMID:19110055; http://dx.doi.org/10.1016/j.ejps.2008.11.013
109. E.Mata, M.Igartua, M.E.Patarroyo, J.L.Pedraz, R.M.Hernandez. Enhancing immunogenicity to PLGA microparticulate systems by incorporation of alginate and RGD-modified alginate. Eur J Pharm Sci 2011; 44:32-40; PMID:21699977; http://dx.doi.org/10.1016/j.ejps.2011.05.015
110. P.J.Tacken, R.Torensma, C.G.Figdor. Targeting antigens to dendritic cells in vivo. Immunobiology 2006; 211:599-608; PMID:16920498; http://dx.doi.org/10.1016/j.imbio.2006.05.021
111. A.Haddadi, S.Hamdy, Z.Ghotbi, J.Samuel, A.Lavasanifar. Immunoadjuvant activity of the nanoparticles' surface modified with mannan. Nanotechnology 2014; 25:355101; PMID:25119543; http://dx.doi.org/10.1088/0957-4484/25/35/355101
112. P.J.Tacken, I.J.de Vries, R.Torensma, C.G.Figdor. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802; PMID:17853902; http://dx.doi.org/10.1038/nri2173
113. S.Hamdy, A.Haddadi, A.Shayeganpour, J.Samuel, A.Lavasanifar. Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles. Pharm Res 2011; 28:2288-301; PMID:21560020; http://dx.doi.org/10.1007/s11095-011-0459-9
114. Z.Ghotbi, A.Haddadi, S.Hamdy, R.W.Hung, J.Samuel, A.Lavasanifar. Active targeting of dendritic cells with mannan-decorated PLGA nanoparticles. J Drug Target 2010; 19(4):281-92.
115. V.Apostolopoulos, G.A.Pietersz, S.Gordon, L.Martinez-Pomares, I.F.McKenzie. Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway. Eur J Immunol 2000; 30:1714-23; PMID:10898509; http://dx.doi.org/10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO;2-C
116. V.Apostolopoulos, G.A.Pietersz, B.E.Loveland, M.S.Sandrin, I.F.McKenzie. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc Natl Acad Sci U S A 1995; 92:10128-32; PMID:7479739; http://dx.doi.org/10.1073/pnas.92.22.10128
117. D.Raghuwanshi, V.Mishra, M.R.Suresh, K.Kaur. A simple approach for enhanced immune response using engineered dendritic cell targeted nanoparticles. Vaccine 2012; 30:7292-9; PMID:23022399; http://dx.doi.org/10.1016/j.vaccine.2012.09.036
118. L.C.Bonifaz, D.P.Bonnyay, A.Charalambous, D.I.Darguste, S.Fujii, H.Soares, M.K.Brimnes, B.Moltedo, T.M.Moran, R.M.Steinman. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:15024047; http://dx.doi.org/10.1084/jem.20032220
119. Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, Trottein F, Faveeuw C. Targeted delivery of alpha-galactosylceramide to CD8alpha+ dendritic cells optimizes type I NKT cell-based antitumor responses. J Immunol 2014; 193:961-9.
120. M.F.Bachmann, G.T.Jennings. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10:787-96.; PMID:20948547; http://dx.doi.org/10.1038/nri2868